docetaxel anhydrous has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Christodoulou, C; Dionysopoulos, D; Fountzilas, G; Kalogeras, KT; Korantzis, I; Kotoula, V; Koutras, A; Linardou, H; Papakostas, P; Papaxoinis, G; Pectasides, D; Samantas, E; Soupos, N | 1 |
2 other study(ies) available for docetaxel anhydrous and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Neovascularization, Pathologic; Receptor, ErbB-2; Severity of Illness Index; Taxoids; Transforming Growth Factor beta1 | 2012 |